[{"id":"868ab017-feca-462a-908a-0cf81a5b86b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04310007","created_at":"2021-01-18T20:53:46.863Z","updated_at":"2025-02-25T16:37:47.177Z","phase":"Phase 2","brief_title":"Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04310007","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • KRAS • BRAF • ALK • ROS1","pipe":" | ","alterations":" KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative","tags":["EGFR • PD-L1 • KRAS • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • gemcitabine • docetaxel • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cyramza (ramucirumab) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • lexatumumab (ETR2-ST01) • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 117","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-06"},{"id":"701c790f-d71e-4882-8490-72c4deac7a2f","acronym":"BYON3521.001","url":"https://clinicaltrials.gov/study/NCT05323045","created_at":"2022-04-12T14:52:58.036Z","updated_at":"2024-07-02T16:34:37.322Z","phase":"Phase 1","brief_title":"A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521","source_id_and_acronym":"NCT05323045 - BYON3521.001","lead_sponsor":"Byondis B.V.","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • MET mutation • MET expression • MET positive","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET mutation • MET expression • MET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BYON3521"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 03/21/2022","start_date":" 03/21/2022","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-06-07"},{"id":"cc3db3b8-b381-4e3e-8f3a-6478dfee9150","acronym":"","url":"https://clinicaltrials.gov/study/NCT04617314","created_at":"2021-01-19T20:33:47.665Z","updated_at":"2024-07-02T16:35:18.619Z","phase":"Phase 1","brief_title":"A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT04617314","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" MET","pipe":" | ","alterations":" MET positive","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RC108"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 03/10/2021","start_date":" 03/10/2021","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-02-20"},{"id":"4b9588e8-34ef-4f39-9824-5762f04f1e2a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05628857","created_at":"2022-11-29T15:57:45.073Z","updated_at":"2024-07-02T16:35:27.481Z","phase":"Phase 2","brief_title":"A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor","source_id_and_acronym":"NCT05628857","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" MET","pipe":" | ","alterations":" MET positive","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RC108"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 11/11/2022","start_date":" 11/11/2022","primary_txt":" Primary completion: 10/15/2024","primary_completion_date":" 10/15/2024","study_txt":" Completion: 10/15/2025","study_completion_date":" 10/15/2025","last_update_posted":"2023-11-30"},{"id":"d0409497-b75d-44b0-85df-4030915dc145","acronym":"HS-10241-301","url":"https://clinicaltrials.gov/study/NCT06110663","created_at":"2023-11-01T15:12:24.088Z","updated_at":"2024-07-02T16:35:30.877Z","phase":"Phase 3","brief_title":"A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy","source_id_and_acronym":"NCT06110663 - HS-10241-301","lead_sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","biomarkers":" MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR T790M • MET positive","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR T790M • MET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • pemetrexed • Ameile (aumolertinib) • dalmelitinib (HS-10241)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 314","initiation":"Initiation: 12/30/2023","start_date":" 12/30/2023","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2023-11-01"},{"id":"a44fd9da-48a5-4030-9451-0e84dbc43d2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05430386","created_at":"2022-06-24T15:56:28.883Z","updated_at":"2024-07-02T16:35:55.559Z","phase":"Phase 1","brief_title":"Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC","source_id_and_acronym":"NCT05430386","lead_sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","biomarkers":" MET","pipe":" | ","alterations":" EGFR L858R • EGFR exon 19 deletion • MET mutation • MET positive • EGFR T790M negative • EGFR mutation + MET-CEP7 fusion • MET positive + EGFR mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • EGFR exon 19 deletion • MET mutation • MET positive • EGFR T790M negative • EGFR mutation + MET-CEP7 fusion • MET positive + EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ameile (aumolertinib) • dalmelitinib (HS-10241)"],"overall_status":"Recruiting","enrollment":" Enrollment 174","initiation":"Initiation: 01/05/2022","start_date":" 01/05/2022","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-02-14"},{"id":"cc6303ef-0da1-4ff1-b18d-e9ebcad3bf43","acronym":"","url":"https://clinicaltrials.gov/study/NCT04930432","created_at":"2021-06-18T23:52:45.253Z","updated_at":"2024-07-02T16:36:19.267Z","phase":"Phase 1/2","brief_title":"Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors","source_id_and_acronym":"NCT04930432","lead_sponsor":"Betta Pharmaceuticals Co., Ltd.","biomarkers":" EGFR • IFNG • IL6 • TNFA • CXCL8 • IL2 • IL10 • IL1B","pipe":" | ","alterations":" MET positive","tags":["EGFR • IFNG • IL6 • TNFA • CXCL8 • IL2 • IL10 • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pamvatamig (MCLA-129)"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 09/24/2021","start_date":" 09/24/2021","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2021-12-21"},{"id":"d13c635a-1aa3-4a77-af1d-2a98cdcc79c8","acronym":"LUNG-MAP SUB-STUDY","url":"https://clinicaltrials.gov/study/NCT03574753","created_at":"2021-01-18T17:35:20.794Z","updated_at":"2024-07-02T16:36:22.818Z","phase":"Phase 2","brief_title":"Lung-MAP S1400K: c-MET Positive","source_id_and_acronym":"NCT03574753 - LUNG-MAP SUB-STUDY","lead_sponsor":"Southwest Oncology Group","biomarkers":" MET","pipe":" | ","alterations":" MET positive","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Emrelis (telisotuzumab vedotin-tllv)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 03/16/2018","start_date":" 03/16/2018","primary_txt":" Primary completion: 12/21/2019","primary_completion_date":" 12/21/2019","study_txt":" Completion: 07/30/2021","study_completion_date":" 07/30/2021","last_update_posted":"2021-10-18"},{"id":"94fabb12-5332-4639-9c1b-0c494b08b3f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT01999972","created_at":"2021-01-18T09:07:42.631Z","updated_at":"2024-07-02T16:36:40.719Z","phase":"Phase 1b","brief_title":"A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT01999972","lead_sponsor":"Pfizer","biomarkers":" MET • HGF • FLT4","pipe":" | ","alterations":" MET positive","tags":["MET • HGF • FLT4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • axitinib"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 02/26/2014","start_date":" 02/26/2014","primary_txt":" Primary completion: 02/22/2017","primary_completion_date":" 02/22/2017","study_txt":" Completion: 09/05/2019","study_completion_date":" 09/05/2019","last_update_posted":"2020-09-24"},{"id":"d44ae7ac-0c9e-44e0-9485-99103e6996fd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04228406","created_at":"2021-01-18T20:34:28.306Z","updated_at":"2024-07-02T16:36:51.354Z","phase":"Phase 1","brief_title":"Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy Evaluation of GST-HG161","source_id_and_acronym":"NCT04228406","lead_sponsor":"Fujian Cosunter Pharmaceutical Co. Ltd","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • MET expression • MET positive","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET expression • MET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemnelatinib (GST-HG161)"],"overall_status":"Unknown status","enrollment":" Enrollment 62","initiation":"Initiation: 07/01/2019","start_date":" 07/01/2019","primary_txt":" Primary completion: 09/30/2020","primary_completion_date":" 09/30/2020","study_txt":" Completion: 12/31/2020","study_completion_date":" 12/31/2020","last_update_posted":"2020-01-14"},{"id":"ad059291-02b5-4149-a5a6-12c4efa5c771","acronym":"","url":"https://clinicaltrials.gov/study/NCT03672305","created_at":"2021-01-18T18:00:49.358Z","updated_at":"2024-07-02T16:37:06.818Z","phase":"Phase 1","brief_title":"Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC","source_id_and_acronym":"NCT03672305","lead_sponsor":"The Second Hospital of Nanjing Medical University","biomarkers":" PD-L1 • MET","pipe":" | ","alterations":" MET amplification • MET positive","tags":["PD-L1 • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET positive"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 10/01/2018","start_date":" 10/01/2018","primary_txt":" Primary completion: 10/30/2019","primary_completion_date":" 10/30/2019","study_txt":" Completion: 10/30/2019","study_completion_date":" 10/30/2019","last_update_posted":"2018-09-18"},{"id":"f01e63ff-cabb-4f43-915d-19172e8beeed","acronym":"","url":"https://clinicaltrials.gov/study/NCT02031744","created_at":"2021-01-18T09:19:00.776Z","updated_at":"2024-07-02T16:37:24.418Z","phase":"Phase 3","brief_title":"A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02031744","lead_sponsor":"Hoffmann-La Roche","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • MET positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • onartuzumab (RG3638)"],"overall_status":"Completed","enrollment":" Enrollment 530","initiation":"Initiation: 01/22/2014","start_date":" 01/22/2014","primary_txt":" Primary completion: 01/06/2016","primary_completion_date":" 01/06/2016","study_txt":" Completion: 01/06/2016","study_completion_date":" 01/06/2016","last_update_posted":"2017-03-14"},{"id":"8981fa9c-600a-4e15-b8dd-b861c2b84b69","acronym":"","url":"https://clinicaltrials.gov/study/NCT02435108","created_at":"2021-01-18T11:39:31.292Z","updated_at":"2024-07-02T16:37:25.581Z","phase":"Phase 2","brief_title":"A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy","source_id_and_acronym":"NCT02435108","lead_sponsor":"Samsung Medical Center","biomarkers":" MET","pipe":" | ","alterations":" MET positive","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib)"],"overall_status":"Completed","enrollment":" Enrollment 2","initiation":"Initiation: 05/15/2014","start_date":" 05/15/2014","primary_txt":" Primary completion: 01/01/2016","primary_completion_date":" 01/01/2016","study_txt":" Completion: 07/15/2016","study_completion_date":" 07/15/2016","last_update_posted":"2017-02-17"},{"id":"70d12bc0-2116-4871-8e9d-2d4a1d101786","acronym":"","url":"https://clinicaltrials.gov/study/NCT02977364","created_at":"2021-01-18T14:38:17.876Z","updated_at":"2024-07-02T16:37:27.355Z","phase":"Phase 1","brief_title":"A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours","source_id_and_acronym":"NCT02977364","lead_sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","biomarkers":" MET","pipe":" | ","alterations":" MET positive","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dalmelitinib (HS-10241)"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 11/01/2018","primary_completion_date":" 11/01/2018","study_txt":" Completion: 11/01/2021","study_completion_date":" 11/01/2021","last_update_posted":"2016-11-30"},{"id":"bab0d2e3-cdf6-489a-8032-a35d5a508aea","acronym":"","url":"https://clinicaltrials.gov/study/NCT01662869","created_at":"2021-01-18T07:11:05.853Z","updated_at":"2024-07-02T16:37:27.962Z","phase":"Phase 3","brief_title":"A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer","source_id_and_acronym":"NCT01662869","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2","pipe":" | ","alterations":" MET positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium • onartuzumab (RG3638)"],"overall_status":"Completed","enrollment":" Enrollment 564","initiation":"Initiation: 11/01/2012","start_date":" 11/01/2012","primary_txt":" Primary completion: 12/01/2015","primary_completion_date":" 12/01/2015","study_txt":" Completion: 12/01/2015","study_completion_date":" 12/01/2015","last_update_posted":"2016-11-02"},{"id":"5a93b740-6910-4d00-b8f2-72cf65ee8680","acronym":"","url":"https://clinicaltrials.gov/study/NCT01590719","created_at":"2021-01-18T06:47:29.333Z","updated_at":"2024-07-02T16:37:29.936Z","phase":"Phase 2","brief_title":"A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer","source_id_and_acronym":"NCT01590719","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2","pipe":" | ","alterations":" MET positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium • onartuzumab (RG3638)"],"overall_status":"Completed","enrollment":" Enrollment 123","initiation":"Initiation: 07/01/2012","start_date":" 07/01/2012","primary_txt":" Primary completion: 10/01/2014","primary_completion_date":" 10/01/2014","study_txt":" Completion: 10/01/2014","study_completion_date":" 10/01/2014","last_update_posted":"2016-08-09"},{"id":"b3fcc71c-45ea-43d9-8804-7feab6152f22","acronym":"SARMET","url":"https://clinicaltrials.gov/study/NCT01391533","created_at":"2021-01-18T05:42:43.337Z","updated_at":"2024-07-02T16:37:32.819Z","phase":"Phase 1","brief_title":"Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT01391533 - SARMET","lead_sponsor":"Sanofi","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • MET expression • MET positive","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET expression • MET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SAR 125844"],"overall_status":"Completed","enrollment":" Enrollment 72","initiation":"Initiation: 07/01/2011","start_date":" 07/01/2011","primary_txt":" Primary completion: 04/01/2016","primary_completion_date":" 04/01/2016","study_txt":" Completion: 04/01/2016","study_completion_date":" 04/01/2016","last_update_posted":"2016-04-13"}]